For the year ending 2025-12-31, AVBP had -$28,753K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -166,308 |
| Stock-based compensation expense | 12,520 |
| Amortization/accretion of bond discounts/premiums | -3,026 |
| Prepaid expenses and other current assets | 12,561 |
| Accounts payable | 2,141 |
| Accrued expenses | 6,667 |
| Operating lease liabilities | -21 |
| Net cash used in operating activities | -160,588 |
| Purchase of short-term and long-term investments | 272,934 |
| Sales and maturities of short-term and long-term investments | 201,706 |
| Net cash used in investing activities | -71,228 |
| Proceeds from issuance of common stock, net of issuance costs | 202,631 |
| Proceeds from the exercise of stock options | 502 |
| Payment of deferred financing costs | 70 |
| Net cash provided by financing activities | 203,063 |
| Net decrease in cash and cash equivalents | -28,753 |
| Cash and cash equivalents at beginning of the year | 74,293 |
| Cash and cash equivalents at end of the year | 45,540 |
ArriVent BioPharma, Inc. (AVBP)
ArriVent BioPharma, Inc. (AVBP)